Published online before print January 17, 2005, doi: 10.1161/01.CIR.0000153356.72810.97
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2005;111:321-327.)
© 2005 American Heart Association, Inc.
Interventional Cardiology |
Relationship of Late Loss in Lumen Diameter to Coronary Restenosis in Sirolimus-Eluting Stents
From the Brigham and Women’s Hospital (L.M., E.J.O., R.E.K.), Harvard Medical School (A.J.O., L.M., E.J.O., R.E.K., D.E.C.), and Harvard Clinical Research Institute (L.M., R.E.K., D.E.C., C.S.), Boston, Mass; Lenox Hill Heart and Vascular Institute (J.W.M., M.B.L.), New York, NY; Mayo Clinic (D.R.H.), Rochester, Minn; Scripps Clinic (P.S.T.), La Jolla, Calif; Center for Cardiology and Vascular Intervention (J.S.), Hamburg, Germany; Department of Cardiology and Angiology (G.B.), University Hospital, Münster, Germany; Beth Israel Deaconess Medical Center (D.E.C.), Boston, Mass; Ohio Heart Health Center (D.J.K.), Cincinnati, Ohio; and Cordis Corporation (B.G.F., D.J.D.), Warren, NJ.
Correspondence to Richard E. Kuntz, MD, MSc, BC-3-012N, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02116. E-mail rkuntz{at}partners.org
Received August 2, 2004; revision received September 26, 2004; accepted October 28, 2004.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionConclusionsReferences |
|---|
Background— Observed rates of restenosis after drug-eluting stenting are low (<10%). Identification of a reliable and powerful angiographic end point will be useful in future trials.
Methods and Results— Late loss (postprocedural minimum lumen diameter minus 8-month minimum lumen diameter) was measured in the angiographic cohorts of the SIRIUS (n=703) and E-SIRIUS (n=308) trials. Two techniques, the standard normal approximation and an optimized power transformation, were used to predict binary angiographic restenosis rates and compare them with observed restenosis rates. The mean in-stent late loss observed in the SIRIUS trial was 0.17±0.45 mm (sirolimus) versus 1.00±0.70 mm (control). If a normal distribution was assumed, late loss accurately estimated in-stent binary angiographic restenosis for the control arm (predicted 35.4% versus observed 35.4%) but underestimated it in the sirolimus arm (predicted 0.6% versus observed 3.2%). Power transformation improved the reliability of the estimate in the sirolimus arm (predicted 3.2% [CI 1.0% to 6.7%]) with similar improvements in the E-SIRIUS trial (predicted 4.0% [CI 1.2% to 7.0%] versus observed 3.9%). In the sirolimus-eluting stent arm, in-stent late loss correlated better with target-lesion revascularization than in-segment late loss (c-statistic=0.915 versus 0.665).
Conclusions— Because distributions of late loss with a low mean are right-skewed, the use of a transformation improves the accuracy of predicting low binary restenosis rates. Late loss is monotonically correlated with the probability of restenosis and yields a more efficient estimate of the restenosis process in the era of lower binary restenosis rates.
Key Words: angioplasty • stents • restenosis
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionConclusionsReferences |
|---|
The evaluation of percutaneous coronary devices over the past 20 years has relied on an estimation of cumulative late-term failure, manifested largely by recurrent renarrowing of the treated coronary segment.1 A variety of continuous end points, including the minimum lumen diameter (MLD) or percent diameter stenosis at 6 to 9 months after intervention, precisely describe the stable long-term result on the treated coronary segment.2 Binary end points that classify a treatment as ultimately successful or unsuccessful, such as binary angiographic restenosis (BAR) or target-lesion revascularization (TLR), are more commonly compared across competing coronary treatments. Although BAR is merely the frequency of percent diameter stenosis greater than an arbitrary threshold of 50% and is itself poorly correlated with the need for repeat intervention for any given subject,3 its rate in trials has been highly correlated with the rate of TLR.4 The moderately high rates of BAR and TLR seen in conventional trials (15% to 40%) have provided enough power for adequate discrimination between competing percutaneous therapies enrolling
1000 subjects.5–9
In contrast, several recent drug-eluting stent (DES) trials have demonstrated a breakthrough in the reduction of late restenosis compared with bare metal stents, with a consistent incidence of BAR and TLR below 10%.10,11 Even with the achieved low rates, which may underestimate the rate in actual practice or in high-risk groups,12–17 cost-effectiveness analysis provides economic and quality-of-life incentives to distinguish therapies with restenosis rates below 10%.18 However, the statistical power available to determine superiority (or demonstrate noninferiority) in competing DES treatments is markedly reduced when sample sizes of 2000 subjects or less are used. A reevaluation of continuous restenosis metrics as discriminators between competing DES therapies is necessary, especially for underpowered pilot (50 to 150 subjects) and pivotal (1000 subjects) trials. The traditional angiographic variables, late MLD and percent diameter stenosis, are powerful continuous measures, but late loss (postprocedural MLD minus 8-month MLD) has the unique ability to distinguish the magnitude of late intimal renarrowing from baseline and procedural variables (reference vessel diameter and residual stenosis). We sought to evaluate the reliability of late loss in providing a monotonic (nondecreasing) metric of antirestenosis effect and its ability to predict relative measures of restenosis in the DES era.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionConclusionsReferences |
|---|
Study Population
Primary data were analyzed from the SIRIUS (Sirolimus-Eluting Bx VELOCITY Balloon-Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and E-SIRUS (European Sirolimus-Eluting Bx VELOCITY Balloon-Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions) randomized trials.10,19 The SIRIUS trial was a 1101-patient, multicenter, randomized, double-blind evaluation of the sirolimus-eluting Bx Velocity stent compared with the standard Bx Velocity stent. Patients with a de novo coronary artery stenosis 15 to 30 mm in length in a 2.5- to 3.5-mm diameter vessel were eligible. E-SIRIUS was a 353-patient, multicenter, randomized trial of the same active and control stent arms, performed in Europe. Patients with a de novo coronary artery stenosis 15 to 32 mm in length in a 2.5- to 3.0-mm diameter vessel were eligible. Other clinical inclusion and exclusion criteria were similar to the SIRIUS trial. All investigational sites received approval from their local hospital institutional review boards.
The first 850 patient observations from the SIRIUS trial, the 8-month angiographic follow-up cohort, were used to develop the late-loss models (prediction cohort; complete follow-up in 703 patients). The 353-patient E-SIRIUS trial required 8-month follow-up in all subjects (completed in 308 subjects) and was used as the test cohort for the late-loss models generated from the SIRIUS study. Further predictions of relative restenosis based on late-loss estimates were made for the TAXUS (TAXUS Express Paclitaxel-Eluting Stent for Treatment of De Novo Lesions) IV trial.11
Angiographic Analysis
Standard image acquisition was performed at the clinical sites as described previously.10,19 Cineangiograms for both trials were forwarded to the Brigham and Women’s Hospital Angiographic Core Laboratory for review by observers blinded to the treatment assignment.
All procedural and follow-up angiograms were reviewed with standard morphological criteria.20–22 Quantitative angiographic analysis was performed with a validated automated edge-detection algorithm (Medis CMS).23 A 5-mm segment of reference diameter proximal and distal to the stenosis was used to calculate the average reference vessel diameter. MLDs were measured within the stent (in-stent analysis) and within the segment including 5 mm proximal and distal to the stent margins (in-segment analysis).23a
Definitions
Late loss was defined as the MLD immediately after the procedure minus the MLD at 8-month follow-up. Percent diameter stenosis was defined as [1–(MLD/reference vessel diameter)x100]. BAR was defined as a >50% diameter stenosis at follow-up. Lesion length was defined as the axial extent of the lesion that contained a shoulder-to-shoulder lumen reduction by 
20%. TLR was defined as clinically driven revascularization of the target lesion by 9 months of follow-up and was adjudicated by an independent Clinical Events Committee.
Statistical Analysis
Ordinal variables are expressed as frequencies, and continuous variables are expressed as mean±SD. Binary variables were compared with 
2 analysis, and continuous variables were evaluated with the Student’s t test. A 2-sided probability value 
0.05 was considered significant. Statistical analyses were performed in SAS (version 8.2) unless otherwise noted.
Prediction of Angiographic Restenosis Rate From Late Loss
The normality of the distributions of late loss (in-stent and in-segment) were tested in each arm (active and control) of the SIRIUS trial with the Kolmogorov-Smirnov test. The fit of other parametric distributions (Gamma, Weibull) and the following transformations of late loss were examined systematically: log, square root, log normal, log-logistic, and power. The power-transformation procedure was the most flexible in transforming the late-loss distribution. The BOXCOX procedure (STATA) was used to screen the fit of the power transformation, then the optimum power (ranging from 0 to 1) was selected to predict the BAR rate observed in each arm of the SIRIUS trial (prediction cohort). The new transformed mean and SD were computed to correct for the rightward skew of the data (see online-only Data Supplement Appendix).
Predicted BAR rates were computed for the standard (normal assumption with the expected value of late loss required to result in a >50% diameter stenosis) and transformed methods and compared with the observed BAR rates for SIRIUS and E-SIRIUS (the test cohort) trials. Confidence intervals (2-sided, 95%) were obtained by simulating 1000 bootstrap samples.24 Percent error was defined as 100 times the difference between the observed rate and the predicted rate divided by the observed rate. Finally, we applied a simple interpolation of the published in-stent late-loss result in the active arm of the TAXUS IV trial11 between the active and control arms of the SIRIUS trial to yield a power-transformation value for TAXUS IV.
Correlation of Late Loss With Clinical Restenosis
The ability of late loss to predict clinical restenosis in the SIRIUS trial was examined with logistic regression models of TLR as the outcome variable and either in-stent or in-segment late loss as the dependent variable. The c-statistic was measured and compared for each (1.0 signifying perfect accuracy).
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionConclusionsReferences |
|---|
Lesion Characteristics
The angiographic characteristics of the lesions are listed in Table 1, which demonstrates highly significant (P<0.001) differences in late loss between the randomized arms for the SIRIUS and E-SIRIUS trials for both in-segment and in-stent late-loss measurements. The control-arm in-segment late-loss means (0.81 mm SIRIUS, 0.80 mm E-SIRIUS) were lower than the in-stent late-loss means (1.00 and 1.05 mm, respectively). The active-arm in-segment late-loss mean was higher than the in-stent mean for the SIRIUS trial (0.24 versus 0.17 mm) but similar in the E-SIRIUS trial (0.19 versus 0.20 mm).
|
Late Loss Is Not Normally Distributed
The distribution of both in-stent and in-segment late loss was not normal for either arm of the trial (in-segment late loss: P<0.01 sirolimus, P<0.01 control; in-stent late loss: P<0.01 sirolimus, P=0.047 control), and the magnitude of right skewness (from a normal distribution where skew=0) was greatest in the sirolimus arm (in-segment late-loss skewness: 0.89 sirolimus, 0.43 control, in-stent: 1.23 sirolimus, 0.32 control; Figures 1 and 2
). Power transformation of in-stent late loss is the optimum method to predict BAR rates from mean late loss.
|
|
Compared with other transformations and nonnormal distributions, the 0.13 power transformation, ie, (late loss)0.13, was the optimum for restoring normality of the right tail of in-segment late loss in the active arm, and the 0.52 power transformation, ie, (late loss)0.52, was the optimum for the control arm. For in-stent late loss, the optimum powers were 0.13 for the active arm and 0.99 for the control arm. The in-segment and in-stent late-loss power transformations were then applied to predict BAR rates. The transformed and nontransformed predictions for both SIRIUS (prediction set) and E-SIRIUS (test set) were compared with the observed rates (Table 2).
|
Predictions based on the normal assumption underestimated restenosis rates in the active arms of SIRIUS and E-SIRIUS trials because of the lack of compensation for right-skewed late-loss distributions. For the SIRIUS trial, the active arm in-stent binary restenosis rate was underestimated by 81% (0.6% predicted rate compared with 3.2% observed rate), and the active in-segment binary restenosis rate was underestimated by 38% (5.5% predicted rate compared with 8.9% observed rate). Similarly, in the test cohort (E-SIRIUS), the transformed active-arm predictions matched better with the observed rates (Table 2). Transformed in-stent late loss was the most predictive of the E-SIRIUS observed BAR rates compared with in-segment transformed late loss and both in-stent and in-segment nontransformed late loss.
In-Stent Late Loss Is Correlated With TLR
We compared predictive models of TLR using in-stent and in-segment late loss. In the active arm, in-stent late loss was a more reliable predictor of TLR (c-statistic 0.915, versus 0.665 for in-segment), whereas TLR from the control arm was similarly predicted from in-stent or in-segment late loss (c-statistic 0.897 versus 0.916, respectively).
Predicting Restenosis Rates for Other DES Systems With In-Stent Late Loss
The optimum transformation power for prediction of BAR from late loss depends on the mean late loss, which varied from 0.13 mm in the active SIRIUS arm to 0.99 mm in the control arm. Interpolation of an in-stent late loss of 0.39 mm observed in the active arm of the TAXUS IV trial11 yielded a power-transformation parameter of 0.36. The published mean reference vessel diameter of 2.75 mm and postprocedural MLD of 2.66 mm in-stent were then used to predict the in-stent BAR rate. With the in-stent late-loss normal approximation (standard method), the predicted in-stent BAR was 3.7%, an underestimate of 39% compared with the observed in-stent BAR rate of 5.5%. The in-stent late-loss transformation approximation, on the other hand, predicted an in-stent BAR rate of 6.1%, an overestimate of only 10% (Figure 3).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionConclusionsReferences |
|---|
Percutaneous coronary therapies have generally been compared on the basis of their restenosis propensities.25 BAR rates and TLR rates ranging between 15% and 25% for stents and between 20% and 40% for other angioplasty devices5–8 allowed detection of modest differences in restenosis rates in clinical trials of fewer than 1000 subjects.26,27
The evaluation of restenosis in the DES era is more complex. In the SIRIUS and TAXUS experience, binary angiographic and clinical restenosis rates are below 10%,10,11 which makes comparisons between competing DES treatments more difficult with sample sizes below 1000 to 2000 subjects. Moreover, the initial evaluation of future candidate DES will likely rely on smaller dose-finding studies of fewer than 100 subjects per test group, in which the infrequent binary restenosis end points will be too insensitive to be effective discriminators.
In the present study, we have evaluated late loss as a potential gauge of restenosis in the DES era. First, in the DES era, in which mean late loss is often a fraction of its SD, right skewness can be overcome with power transformation to allow accurate approximation of BAR rates. Second, late loss is correlated with restenosis: The models in the present study show a monotonic (nondecreasing) relationship between higher late loss and higher restenosis rates in the 2 SIRIUS trials studied, as well as the indirect prediction of the TAXUS IV restenosis rate. Third, in-stent late loss showed a better correlation with TLR than in-segment late loss for the DESs studied. With these robust features, in-stent late loss is a sensitive indicator of restenosis propensity.
Late loss was initially developed as a tool to compare the mechanisms of restenosis between different coronary interventions such as balloon angioplasty, stenting, and atherectomy.28 Within stents, late loss is an absolute measure of neointimal renarrowing, with vascular contraction being prevented by the stent framework.29,30 In-stent neointimal renarrowing, however, is still only 1 factor that determines the probability of restenosis, which is also influenced by the vessel diameter. Commonly reported measures of relative restenosis include percent diameter stenosis and BAR rates. In the pre-DES era, among coronary devices, stents had the lowest relative restenosis but, paradoxically, also had the highest late loss.25 As a result, comparisons of different mechanical percutaneous interventions (angioplasty, stents, atherectomy) relied on relative measures of restenosis. In the case of similar mechanical interventions, however, such as stents with similar acute gains, the need for relative adjustments is reduced, and late loss may be a valuable tool to gauge antirestenosis effect.
Late Loss and Its Skewed Distribution for DESs
With bare metal stenting, late loss has been observed to follow a near-normal distribution.1,31 Bare metal stent trials and registries have demonstrated mean late losses varying from 0.6 to 1.2 mm.5,6,26,27,32–35 The RAVEL trial of the sirolimus-eluting Bx Velocity stent was the first randomized trial to report a stent with an average late loss well below the expected historical range, as well as its own control arm (in-stent late loss –0.01 mm active versus 0.80 mm control), which corresponded to a BAR rate of 0% for the active arm versus 26% in the control arm.36
As the positive mean of any normal distribution is reduced enough so that its spread becomes significantly bounded by zero, it becomes right-skewed. The distribution of late loss for bare metal stents is only marginally skewed by zero. In the case of the sirolimus-eluting stent, however, for which the mean late loss has ranged between –0.01 and 0.24 mm, the late-loss distributions studied are markedly deviated from normal and skewed to the right. In such skewed distributions, the variance, as estimated from the sample SD, no longer accurately denotes the deviation from the mean. If the calculated SD is used to predict binary event rates in this right tail, the predicted binary rates will be underestimated (Figure 4). To accurately study the behavior of such a distribution, either transformation or selection of a distribution that more closely resembles the skewed data becomes necessary rather than reliance on traditional normal methods. The power transformation used in the present study restored a more predictable normal distribution and demonstrated a monotonic relationship between late loss and restenosis.
|
In-Stent Versus In-Segment Late Loss
Whereas in-stent measurements of follow-up MLD have been relied on for the evaluation of virtually all bare metal stents to date,5,6,37 the observation of an exuberant renarrowing at the margins of stents, despite a therapeutic effect within the stent observed in early brachytherapy trials38 and some pilot DES trials,39 termed "edge effect" or "candy-wrapper restenosis," led to inclusion of the zones proximal and distal to the stent for analysis. When the binary variable angiographic restenosis is used, the more inclusive in-segment analysis has the attractive ability to capture events that occur only at the edges, whereas the in-stent analysis does not.
In the present examination of late loss, we also sought to determine whether the in-stent or in-segment analysis was more reliable. We found that for the control arm, in-stent and in-segment analyses were essentially equivalent, with similar c-statistics for predicting TLR. However, in the sirolimus-eluting stent arm, in-stent late loss was much better correlated with TLR than was in-segment late loss.
Ideally, an angiographic measure of neointimal renarrowing would represent the magnitude of maximum change in lumen diameter from the time of stenting to the follow up angiogram across the treatment site and margins. Such a measurement would require a comparison across the 2 time points slice by slice along the length of the vessel, within matched, fine (1 mm) increments. Practically, however, standard techniques of measuring late loss have compared MLDs from a specified zone. The in-stent late-loss calculation compares MLDs both from within the stented zone. The in-segment late-loss calculation compares the minimum of the proximal, distal, and stent zone diameters (in-segment MLD) after stenting and at late follow-up, rather than the maximum late loss from these zones. Thus, the in-segment calculation has the possibility of comparing different regions rather than representing the maximum late loss from among the zones evaluated. Because the greatest acute gain and late loss are usually within the stented zone, the in-segment postprocedural MLD will tend to be measured outside of the stented zone and the follow-up MLD within the stented zone, such that in-segment late loss will necessarily underestimate the maximum late loss (within the stent). In the absence of an edge effect,10,19,36 it is not surprising that the in-stent late-loss measurement best reflects the likelihood of clinical restenosis. The difference in c-statistics for in-stent compared with in-segment late loss reflects the better correlation of in-stent late loss with the probability of TLR when sirolimus-eluting stents are used.
Other Continuous Absolute and Relative Angiographic End Points
Two other angiographic variables should be considered as alternatives: an absolute measure of restenosis, late MLD, and a relative measure of restenosis, late percent diameter stenosis. These continuous measures are correlated with restenosis. The unique advantage of late loss is the ability to distinguish the magnitude of late intimal renarrowing from baseline and procedural variables such as reference vessel diameter and residual stenosis. Whereas percent diameter stenosis is directly linked to the likelihood of target-vessel revascularization in a given patient, late loss isolates the neointimal hyperplasia component of the restenosis process for a given DES.
Clinical Implications for In-Stent Late Loss
Proper binary restenosis rate estimation from late loss requires mathematical transformation of the data, because traditional extrapolation will diminish the actual differences in binary restenosis rates for any 2 comparable values of late loss. This underestimation error is most pronounced at low restenosis rates where current DES clinical trials range. This method of transformation will require future validation as additional DES studies are published. Although higher late-loss values correlate positively with higher restenosis rates, to what extent small differences in late loss are clinically meaningful between comparative DES systems may be more difficult to answer. These small differences may have the most important effects in high-restenosis-risk groups.
Study Limitations
Although vessel diameter may have a smaller effect on late loss than on relative measures of restenosis, such as other restenosis end points, late loss is best used to compare stents between groups that have similar acute gain, lesion lengths, and diabetes prevalence, as in a randomized, controlled trial. Finally, although in-stent late loss was most reliable for prediction of angiographic and clinical restenosis in sirolimus-eluting stents, analysis of the proximal and distal zones is still mandatory to detect edge effects when new DESs are studied.
|
Conclusions |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionConclusionsReferences |
|---|
Late loss is a robust end point that may be used in future trials to discriminate between new DESs for which binary rates are anticipated to be low. An angiographic surrogate for neointimal hyperplasia, in-stent late loss is positively correlated with other measures of relative restenosis and clinical restenosis and may be useful, particularly in early trials in which sample size is limited.
|
Footnotes |
|---|
Consulting Editor for this article was Elizabeth G. Nabel, MD.
The online-only Data Supplement, which contains an Appendix, can be found with this article at http://www.circulationaha.org.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionConclusionsReferences |
|---|
1. Kuntz RE, Baim DS. Defining coronary restenosis: newer clinical and angiographic paradigms. Circulation. 1993; 88: 1310–1323.
2. Kimura T, Yokoi H, Nakagawa Y, Tamura T, Kaburagi S, Sawada Y, Sato Y, Hamasaki N, Nosaka H, Nobuyoshi M. Three-year follow-up after implantation of metallic coronary-artery stents. N Engl J Med. 1996; 334: 561–566.
3. Gordon PC, Friedrich SP, Piana RN, Kugelmass AD, Leidig GA, Gibson CM, Cohen DJ, Carrozza JP, Kuntz RE, Baim DS. Is 40% to 70% diameter narrowing at the site of previous stenting or directional coronary atherectomy clinically significant? Am J Cardiol. 1994; 74: 26–32.[CrossRef][Medline] [Order article via Infotrieve]
4. Cutlip DE, Chauhan MS, Baim DS, Ho KK, Popma JJ, Carrozza JP, Cohen DJ, Kuntz RE. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol. 2002; 40: 2082–2089.
5. Baim DS, Cutlip DE, Midei M, Linnemeier TJ, Schreiber T, Cox D, Kereiakes D, Popma JJ, Robertson L, Prince R, Lansky AJ, Ho KK, Kuntz RE. Final results of a randomized trial comparing the MULTI-LINK stent with the Palmaz-Schatz stent for narrowings in native coronary arteries. Am J Cardiol. 2001; 87: 157–162.[CrossRef][Medline] [Order article via Infotrieve]
6. Baim DS, Cutlip DE, O’Shaughnessy CD, Hermiller JB, Kereiakes DJ, Giambartolomei A, Katz S, Lansky AJ, Fitzpatrick M, Popma JJ, Ho KK, Leon MB, Kuntz RE. Final results of a randomized trial comparing the NIR stent to the Palmaz-Schatz stent for narrowings in native coronary arteries. Am J Cardiol. 2001; 87: 152–156.[CrossRef][Medline] [Order article via Infotrieve]
7. Mauri L, Bonan R, Weiner BH, Legrand V, Bassand JP, Popma JJ, Niemyski P, Prpic R, Ho KK, Chauhan MS, Cutlip DE, Bertrand OF, Kuntz RE. Cutting balloon angioplasty for the prevention of restenosis: results of the Cutting Balloon Global Randomized Trial. Am J Cardiol. 2002; 90: 1079–1083.[CrossRef][Medline] [Order article via Infotrieve]
8. Mauri L, Reisman M, Buchbinder M, Popma JJ, Sharma SK, Cutlip DE, Ho KK, Prpic R, Zimetbaum PJ, Kuntz RE. Comparison of rotational atherectomy with conventional balloon angioplasty in the prevention of restenosis of small coronary arteries: results of the Dilatation vs Ablation Revascularization Trial Targeting Restenosis (DART). Am Heart J. 2003; 145: 847–854.[CrossRef][Medline] [Order article via Infotrieve]
9. Baim DS, Cutlip DE, Sharma SK, Ho KK, Fortuna R, Schreiber TL, Feldman RL, Shani J, Senerchia C, Zhang Y, Lansky AJ, Popma JJ, Kuntz RE. Final results of the Balloon vs Optimal Atherectomy Trial (BOAT). Circulation. 1998; 97: 322–331.
10. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O’Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003; 349: 1315–1323.
11. Stone GW, Ellis SG, Cox DA, Hermiller J, O’Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russel ME. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004; 350: 221–230.
12. Lemos PA, Serruys PW, van Domburg RT, Saia F, Arampatzis CA, Hoye A, Degertekin M, Tanabe K, Daemen J, Liu TK, McFadden E, Sianos G, Hofma SH, Smits PC, van der Giessen WJ, de Feyter PJ. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation. 2004; 109: 190–195.
13. Colombo A, Moses JW, Morice MC, Ludwig J, Holmes DR Jr, Spanos V, Louvard Y, Desmedt B, Di Mario C, Leon MB. Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation. 2004; 109: 1244–1249.
14. Hoye A, Tanabe K, Lemos PA, Aoki J, Saia F, Arampatzis C, Degertekin M, Hofma SH, Sianos G, McFadden E, van der Giessen WJ, Smits PC, de Feyter PJ, van Domburg RT, Serruys PW. Significant reduction in restenosis after the use of sirolimus-eluting stents in the treatment of chronic total occlusions. J Am Coll Cardiol. 2004; 43: 1954–1958.
15. Saia F, Lemos PA, Hoye A, Sianos G, Arampatzis CA, de Feyter PJ, van der Giessen WJ, Smits PC, van Domburg RT, Serruys PW. Clinical outcomes for sirolimus-eluting stent implantation and vascular brachytherapy for the treatment of in-stent restenosis. Catheter Cardiovasc Interv. 2004; 62: 283–288.[CrossRef][Medline] [Order article via Infotrieve]
16. Tanabe K, Serruys PW, Grube E, Smits PC, Selbach G, van der Giessen WJ, Staberock M, de Feyter P, Muller R, Regar E, Degertekin M, Ligthart JM, Disco C, Backx B, Russell ME. TAXUS III trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation. 2003; 107: 559–564.
17. Moussa I, Leon MB, Baim DS, O’Neill WW, Popma JJ, Buchbinder M, Midwall J, Simonton CA, Keim E, Wang P, Kuntz RE, Moses JW. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation. 2004; 109: 2273–2278.
18. Cohen DJ, Bakhai A, Shi C, Githiora L, Lavelle T, Berezin RH, Leon MB, Moses JW, Carrozza JP Jr, Zidar JP, Kuntz RE. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) Trial. Circulation. 2004; 110: 508–514.
19. Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, Breithardt G. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet. 2003; 362: 1093–1099.[CrossRef][Medline] [Order article via Infotrieve]
20. Ellis SG, Vandormael MG, Cowley MJ, DiSciascio G, Deligonul U, Topol EJ, Bulle TM, for the Multivessel Angioplasty Prognosis Study Group. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease: implications for patient selection. Circulation. 1990; 82: 1193–1202.
21. Ryan TJ, Faxon DP, Gunnar RM, Kennedy JW, King SB III, Loop FD, Peterson KL, Reeves TJ, Williams DO, Winters WL Jr. Guidelines for percutaneous transluminal coronary angioplasty: a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). Circulation. 1988; 78: 486–502.
22. Popma JJ. Coronary angiography and intravascular ultrasonography. In: Braunwald E, Zipes DP, Libby P, eds. Heart Disease. 6th ed. New York, NY: WB Saunders; 2001: 414.
23. van der Zwet PM, Reiber JH. A new approach for the quantification of complex lesion morphology: the gradient field transform: basic principles and validation results. J Am Coll Cardiol. 1994; 24: 216–224.[Abstract]
23. Popma JJ, Leon MB, Moses JW, Holmes DR Jr, Cox N, Fitzpatrick M, Douglas J, Lambert C, Mooney M, Yakubov S, Kuntz RE. Quantitative assessment of angiographic restenosis after sirolimus-eluting stent implantation in native coronary arteries. Circulation. 2004; 110: 3773–3780.
24. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. New York, NY: Chapman & Hal; 1993.
25. Kuntz RE, Gibson CM, Nobuyoshi M, Baim DS. Generalized model of restenosis after conventional balloon angioplasty, stenting and directional atherectomy. J Am Coll Cardiol. 1993; 21: 15–25.[Abstract]
26. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M, Cleman M, Heuser R, Almond D, Teirstein PS, Fish RD, Colombo A, Brinker J, Moses J, Shaknovich A, Hirshfeld J, Bailey S, Ellis S, Rake R, Goldberg S, for the Stent Restenosis Study Investigators. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 1994; 331: 496–501.
27. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P, Berlardi J, Sigwart U, Columbo A, Goy JJ, van den Heuvel P, Delcan J, Morel MA. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 1994; 331: 489–495.
28. Kuntz RE, Safian RD, Levine MJ, Reis GJ, Diver DJ, Baim DS. Novel approach to the analysis of restenosis after the use of three new coronary devices. J Am Coll Cardiol. 1992; 19: 1493–1499.[Abstract]
29. Gordon PC, Gibson CM, Cohen DJ, Carrozza JP, Kuntz RE, Baim DS. Mechanisms of restenosis and redilation within coronary stents: quantitative angiographic assessment. J Am Coll Cardiol. 1993; 21: 1166–1174.[Abstract]
30. Post MJ, de Smet BJ, van der Helm Y, Borst C, Kuntz RE. Arterial remodeling after balloon angioplasty or stenting in an atherosclerotic experimental model. Circulation. 1997; 96: 996–1003.
31. Rensing BJ, Hermans WR, Deckers JW, de Feyter PJ, Tijssen JG, Serruys PW. Lumen narrowing after percutaneous transluminal coronary balloon angioplasty follows a near gaussian distribution: a quantitative angiographic study in 1,445 successfully dilated lesions. J Am Coll Cardiol. 1992; 19: 939–945.[Abstract]
32. Kereiakes DJ, Cox DA, Hermiller JB, Midei MG, Bachinsky WB, Nukta ED, Leon MB, Fink S, Marin L, Lansky AJ. Usefulness of a cobalt chromium coronary stent alloy. Am J Cardiol. 2003; 92: 463–466.[CrossRef][Medline] [Order article via Infotrieve]
33. Kastrati A, Mehilli J, Dirschinger J, Dotzer F, Schuhlen H, Neumann FJ, Fleckenstein M, Pfafferott C, Seyfarth M, Schomig A. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation. 2001; 103: 2816–2821.
34. Kastrati A, Dirschinger J, Boekstegers P, Elezi S, Schuhlen H, Pache J, Steinbeck G, Schmitt C, Ulm K, Neumann FJ, Schomig A. Influence of stent design on 1-year outcome after coronary stent placement: a randomized comparison of five stent types in 1,147 unselected patients. Catheter Cardiovasc Interv. 2000; 50: 290–297.[CrossRef][Medline] [Order article via Infotrieve]
35. Lansky AJ, Roubin GS, O’Shaughnessy CD, Moore PB, Dean LS, Raizner AE, Safian RD, Zidar JP, Kerr JL, Popma JJ, Mehran R, Kuntz RE, Leon MB. Randomized comparison of GR-II stent and Palmaz-Schatz stent for elective treatment of coronary stenoses. Circulation. 2000; 102: 1364–1368.
36. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002; 346: 1773–1780.
37. O’Malley AJ, Normand SL, Kuntz RE. Application of models for multivariate mixed outcomes to medical device trials: coronary artery stenting. Stat Med. 2003; 22: 313–336.[CrossRef][Medline] [Order article via Infotrieve]
38. Albiero R, Adamian M, Kobayashi N, Amato A, Vaghetti M, Di Mario C, Colombo A. Short- and intermediate-term results of 32P radioactive beta-emitting stent implantation in patients with coronary artery disease: the Milan Dose-Response Study. Circulation. 2000; 101: 18–26.
39. Serruys PW. ACTION trial. Presented at: European Society of Cardiology Congress, Berlin, Germany, August 31 to September 4, 2002.
This article has been cited by other articles:
 |
|
 |
|
  I. T. Meredith, S. Worthley, R. Whitbourn, D. L. Walters, D. McClean, M. Horrigan, J. J. Popma, D. E. Cutlip, A. DePaoli, M. Negoita, et al. Clinical and Angiographic Results With the Next-Generation Resolute Stent System: A Prospective, Multicenter, First-in-Human Trial J. Am. Coll. Cardiol. Intv., October 1, 2009; 2(10): 977 - 985. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R A Byrne, S Eberle, A Kastrati, A Dibra, G Ndrepepa, R Iijima, J Mehilli, and A Schomig Distribution of angiographic measures of restenosis after drug-eluting stent implantation Heart, October 1, 2009; 95(19): 1572 - 1578. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Latib, J. Cosgrave, and A. Colombo Bimodal distribution of angiographic measures of restenosis: what does it mean? Heart, October 1, 2009; 95(19): 1556 - 1558. [Full Text] [PDF]
|
|
|
|
|
|
J. J. Wykrzykowska, P. W. Serruys, Y. Onuma, T. de Vries, G.-A. van Es, P. Buszman, A. Linke, T. Ischinger, V. Klauss, R. Corti, et al. Impact of Vessel Size on Angiographic and Clinical Outcomes of Revascularization With Biolimus-Eluting Stent With Biodegradable Polymer and Sirolimus-Eluting Stent With Durable Polymer: The LEADERS Trial Substudy J. Am. Coll. Cardiol. Intv., September 1, 2009; 2(9): 861 - 870. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Mehilli, A. Kastrati, R. A. Byrne, O. Bruskina, R. Iijima, S. Schulz, J. Pache, M. Seyfarth, S. Massberg, K.-L. Laugwitz, et al. Paclitaxel- Versus Sirolimus-Eluting Stents for Unprotected Left Main Coronary Artery Disease J. Am. Coll. Cardiol., May 12, 2009; 53(19): 1760 - 1768. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Byrne, R. Iijima, J. Mehilli, S. Pinieck, O. Bruskina, A. Schomig, and A. Kastrati Durability of Antirestenotic Efficacy in Drug-Eluting Stents With and Without Permanent Polymer J. Am. Coll. Cardiol. Intv., April 1, 2009; 2(4): 291 - 299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Pocock, A. J. Lansky, R. Mehran, J. J. Popma, M. P. Fahy, Y. Na, G. Dangas, J. W. Moses, T. Pucelikova, D. E. Kandzari, et al. Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials. J. Am. Coll. Cardiol., January 1, 2008; 51(1): 23 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Tomai, B. Reimers, L. De Luca, A. R. Galassi, A. Gaspardone, A. S. Ghini, V. Ferrero, L. Favero, G. Gioffre, F. Prati, et al. Head-to-Head Comparison of Sirolimus- and Paclitaxel-Eluting Stent in the Same Diabetic Patient With Multiple Coronary Artery Lesions: A prospective, randomized, multicenter study Diabetes Care, January 1, 2008; 31(1): 15 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Baumgart, V. Klauss, F. Baer, F. Hartmann, H. Drexler, W. Motz, H. Klues, S. Hofmann, W. Volker, T. Pfannebecker, et al. One-Year Results of the SCORPIUS Study: A German Multicenter Investigation on the Effectiveness of Sirolimus-Eluting Stents in Diabetic Patients J. Am. Coll. Cardiol., October 23, 2007; 50(17): 1627 - 1634. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Kereiakes, L. Mauri, and R. E. Kuntz Letter by Kereiakes et al Regarding Article, "Stent Thrombosis Late After Implantation of First-Generation Drug-Eluting Stents: A Cause for Concern" Circulation, October 16, 2007; 116(16): e389 - e389. [Full Text] [PDF]
|
|
|
|
|
|
J. Cosgrave, G. Melzi, S. Corbett, G. G.L. Biondi-Zoccai, P. Agostoni, R. Babic, F. Airoldi, A. Chieffo, G. M. Sangiorgi, M. Montorfano, et al. Comparable Clinical Outcomes With Paclitaxel- and Sirolimus-Eluting Stents in Unrestricted Contemporary Practice J. Am. Coll. Cardiol., June 19, 2007; 49(24): 2320 - 2328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. H. Zou, A. J. O'Malley, and L. Mauri Receiver-Operating Characteristic Analysis for Evaluating Diagnostic Tests and Predictive Models Circulation, February 6, 2007; 115(5): 654 - 657. [Full Text] [PDF]
|
|
|
|
 |
|
 F. Alfonso, H. Jneid, A. O. Maree, I. F. Palacios, M. Valgimigli, G. Percoco, L. Bolognese, C. Spaulding, P. Henry, E. Teiger, et al. Drug-eluting stents in primary PCI. N. Engl. J. Med., December 7, 2006; 355(23): 2483 - 2484. [Full Text] [PDF]
|
|
|
|
|
|
B. H. Strauss All Drug-Eluting Stents Are Equal, But Some Drug-Eluting Stents Are More Equal Than Others J. Am. Coll. Cardiol., October 3, 2006; 48(7): 1310 - 1311. [Full Text] [PDF]
|
|
|
|
|
|
F. Alfonso, M.-J. Perez-Vizcayno, R. Hernandez, A. Bethencourt, V. Marti, J. R. Lopez-Minguez, J. Angel, R. Mantilla, C. Moris, A. Cequier, et al. A Randomized Comparison of Sirolimus-Eluting Stent With Balloon Angioplasty in Patients With In-Stent Restenosis: Results of the Restenosis Intrastent: Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting (RIBS-II) Trial J. Am. Coll. Cardiol., June 6, 2006; 47(11): 2152 - 2160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Seabra-Gomes Percutaneous coronary interventions with drug eluting stents for diabetic patients. Heart, March 1, 2006; 92(3): 410 - 419. [Full Text] [PDF]
|
|
|
|
 |
|
 M.-C. Morice, A. Colombo, B. Meier, P. Serruys, C. Tamburino, G. Guagliumi, E. Sousa, H.-P. Stoll, and for the REALITY Trial Investigators Sirolimus- vs Paclitaxel-Eluting Stents in De Novo Coronary Artery Lesions: The REALITY Trial: A Randomized Controlled Trial JAMA, February 22, 2006; 295(8): 895 - 904. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Brener Wish List and REALITY: Choice of Stents and End Points for Treatment of De Novo Coronary Artery Lesions JAMA, February 22, 2006; 295(8): 937 - 938. [Full Text] [PDF]
|
|
|
|
|
|
R. Wessely, A. Schomig, and A. Kastrati Sirolimus and Paclitaxel on Polymer-Based Drug-Eluting Stents: Similar But Different J. Am. Coll. Cardiol., February 21, 2006; 47(4): 708 - 714. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Thomas Are drug eluting stents really worth the money? Heart, January 1, 2006; 92(1): 5 - 7. [Full Text] [PDF]
|
|
|
|
|
|
L. Mauri, E. J. Orav, S. C. Candia, D. E. Cutlip, and R. E. Kuntz Robustness of Late Lumen Loss in Discriminating Drug-Eluting Stents Across Variable Observational and Randomized Trials Circulation, November 1, 2005; 112(18): 2833 - 2839. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Dibra, A. Kastrati, J. Mehilli, J. Pache, H. Schuhlen, N. von Beckerath, K. Ulm, R. Wessely, J. Dirschinger, A. Schomig, et al. Paclitaxel-Eluting or Sirolimus-Eluting Stents to Prevent Restenosis in Diabetic Patients N. Engl. J. Med., August 18, 2005; 353(7): 663 - 670. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Mauri, E. J. Orav, and R. E. Kuntz Late Loss in Lumen Diameter and Binary Restenosis for Drug-Eluting Stent Comparison Circulation, June 28, 2005; 111(25): 3435 - 3442. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Costa and D. I. Simon Molecular Basis of Restenosis and Drug-Eluting Stents Circulation, May 3, 2005; 111(17): 2257 - 2273. [Full Text] [PDF]
|
|
|
|
|
|
D. J. Kereiakes, R. E. Kuntz, L. Mauri, and M. W. Krucoff Surrogates, substudies, and real clinical end points in trials of drug-eluting stents J. Am. Coll. Cardiol., April 19, 2005; 45(8): 1206 - 1212. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||